← Research library

Results of a multicenter observational program to evaluate the effectiveness of complex therapy of patients with chronic cerebrovascular pathology with cognitive impairment with Cortexin and Neuromexol (CORNELia study)

Observational study · 2023

What was studied
CORNELia; 801 patients with chronic cerebral ischemia and cognitive impairment
Main finding
Reports clinical changes with Cortexin plus Neuromexol; biomarkers were assessed in smaller comparison subgroups.

Reported findings and study design

801 chronic-ischemia patients, ages 30–80: 329 men and 472 women. Biomarker subset 30 combination-treated versus 30 comparison patients. Cortexin 10 mg/day for ten days plus Neuromexol 375–750 mg/day for 30 days.

Population or model CORNELia; 801 patients with chronic cerebral ischemia and cognitive impairment

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
NSE biomarker changeTwofold decrease in combination-treated subsetp<0.05
MMSE and drawing-test correlationr=0.5 before and r=0.6 after treatmentp<0.05
Anti-NR2 antibodiesDecreased in both groupsp<0.05
VEGFADecreased only in combination-treated subsetp<0.05

Biomarker comparisons use the 30/30 subset, not all 801 patients; treatment combines two drugs.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Combination treatment does not isolate Cortexin’s contribution.
  • The biomarker subset is not the full cohort; observational findings do not establish causality.

Source details

Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.

Sources checked

Citation

Uncontrolled human reportEnglish abstract

Mashin VV, Belova LA, Kotova EY, Dolgova DR, Statenina AP, Belyaeva YK, Dergacheva AS, Israfilova RR. Results of a multicenter observational program to evaluate the effectiveness of complex therapy of patients with chronic cerebrovascular pathology with cognitive impairment with Cortexin and Neuromexol (CORNELia study) Zh Nevrol Psikhiatr Im S S Korsakova 123(12):34-41. PMID 38147380

Study source ↗ · DOI 10.17116/jnevro202312312134 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards